Soligenix's HyBryte Shows Superior Efficacy and Safety Over Valchlor in CTCL Treatment Study

Soligenix announced the publication of positive results from its comparability study evaluating HyBryte versus Valchlor for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy, highlighting favorable efficacy and safety outcomes. After 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to 20% for Valchlor, with greater average improvement and no treatment-related adverse events reported for HyBryte, while Valchlor patients experienced multiple adverse reactions. This data supports HyBryte's potential as a well-tolerated therapy for early-stage CTCL, addressing a significant unmet medical need in rare disease treatment.

The study results published in Oncology and Therapy represent a meaningful advancement in photodynamic therapy for cutaneous T-cell lymphoma, a rare cancer affecting the skin. The threefold improvement in treatment success rates, combined with the absence of adverse events, positions HyBryte as a potentially superior alternative to existing treatments. This development is particularly important given that CTCL patients often struggle with treatment side effects that can impact quality of life, making well-tolerated options crucial for long-term disease management.

Soligenix's Specialized BioTherapeutics business segment is developing HyBryte as a novel photodynamic therapy utilizing safe visible light, with successful completion of the second Phase 3 study paving the way for regulatory approvals worldwide. The company's broader development programs include expansion of synthetic hypericin into psoriasis and innate defense regulator technology for inflammatory diseases. These research efforts are detailed in the company's regulatory filings available through the SEC's EDGAR database at https://www.sec.gov/edgar/searchedgar/companysearch.

The implications of these study results extend beyond immediate treatment benefits for CTCL patients. The favorable safety profile could enable longer treatment durations and potentially better long-term outcomes, while the efficacy data suggests HyBryte may become a first-line therapy option. As Soligenix moves toward potential commercialization, these results provide strong clinical evidence to support regulatory submissions and physician adoption. The full study methodology and detailed results are available in the Oncology and Therapy publication, accessible through standard academic databases.

This advancement in CTCL treatment comes at a time when rare disease therapies are receiving increased attention from both regulatory agencies and healthcare providers. The significant difference in adverse event profiles between HyBryte and Valchlor highlights the importance of treatment tolerability in chronic conditions like CTCL. With regulatory approvals being sought worldwide, these positive study results could accelerate HyBryte's path to market availability, offering patients a new option that balances efficacy with safety considerations. The company's ongoing research and development efforts continue to explore additional applications for their technology platform across various therapeutic areas.